On March 11, 2024 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported that its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4) has cleared its first cohort within the intratumoural monotherapy arm of the study and is therefore ready to commence combination dosing solid tumour patients with CD19 targeting drug blinatumomab (Blincyto marketed by Amgen) (Press release, Imugene, MAR 11, 2024, https://mcusercontent.com/e38c43331936a9627acb6427c/files/29d98be7-23cc-5260-9e48-e0e4a65ee3ac/Phase_1_onCARlytics_Trial_Advances_to_Combination_Arm.pdf [SID1234640982]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoural (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
The trial is titled: "A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors." See View Source
The combination arm of the study will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto by Amgen which currently is specifically approved only for liquid blood cancers). OnCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto therapy alone and will represent a paradigm shift in solid tumour treatment.
OASIS is a dose escalation trial that will be conducted across multiple sites across the United States, with 52 patients proposed to take part in the trial.
Imugene Managing Director and CEO Leslie Chong said:
"It’s once again a credit to our team and collaborators to see yet another study progressing positively and on schedule. Completion of this first monotherapy intratumoural cohort where ovarian, breast and melanoma patients were dosed paves the way for us to move into an important combination dosing with Blincyto, where we’ll be eager to see the greater potential of onCARlytics in targeting and eradicating solid tumours."
OnCARlytics is a CD19-expressing oncolytic virus that enters tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies.